TR200806298A2 - Farmasötik formülasyon - Google Patents

Farmasötik formülasyon

Info

Publication number
TR200806298A2
TR200806298A2 TR2008/06298A TR200806298A TR200806298A2 TR 200806298 A2 TR200806298 A2 TR 200806298A2 TR 2008/06298 A TR2008/06298 A TR 2008/06298A TR 200806298 A TR200806298 A TR 200806298A TR 200806298 A2 TR200806298 A2 TR 200806298A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical formulation
pharmaceutical compositions
active ingredients
compositions containing
relates
Prior art date
Application number
TR2008/06298A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2008/06298A priority Critical patent/TR200806298A2/tr
Priority to EP09788682.4A priority patent/EP2331079B1/en
Priority to PCT/TR2009/000107 priority patent/WO2010021607A2/en
Publication of TR200806298A2 publication Critical patent/TR200806298A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

Mevcut buluş, stabilite sorunu olan iki aktif maddeyi içeren farmasötik bileşimlere, bu bileşimlerin hazırlanma yöntemlerine ve tıbbi kullanımlarına ilişkindir.
TR2008/06298A 2008-08-22 2008-08-22 Farmasötik formülasyon TR200806298A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2008/06298A TR200806298A2 (tr) 2008-08-22 2008-08-22 Farmasötik formülasyon
EP09788682.4A EP2331079B1 (en) 2008-08-22 2009-08-24 Pharmaceutical formulation
PCT/TR2009/000107 WO2010021607A2 (en) 2008-08-22 2009-08-24 Pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2008/06298A TR200806298A2 (tr) 2008-08-22 2008-08-22 Farmasötik formülasyon

Publications (1)

Publication Number Publication Date
TR200806298A2 true TR200806298A2 (tr) 2010-03-22

Family

ID=41707588

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2008/06298A TR200806298A2 (tr) 2008-08-22 2008-08-22 Farmasötik formülasyon

Country Status (3)

Country Link
EP (1) EP2331079B1 (tr)
TR (1) TR200806298A2 (tr)
WO (1) WO2010021607A2 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201009394A2 (tr) * 2010-11-11 2012-06-21 Bi̇lgi̇ç Mahmut Geliştirilmiş montelukast formülasyonları.
CN102973532A (zh) * 2012-12-28 2013-03-20 南京瑞尔医药有限公司 一种稳定的孟鲁司特钠片剂及制备方法
CN104546851B (zh) * 2013-10-29 2018-01-02 北京韩美药品有限公司 一种颗粒组合物及其制备方法、制剂
PE20161384A1 (es) 2014-02-13 2016-12-28 Incyte Corp Ciclopropilaminas como inhibidores de lsd 1
CN111454188A (zh) 2014-02-13 2020-07-28 因赛特公司 作为lsd1抑制剂的环丙胺
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
BR112018002553A8 (pt) 2015-08-12 2023-01-24 Incyte Corp Sais de um inibidor de lsd1
CN105616368B (zh) * 2016-01-22 2017-02-22 山东新时代药业有限公司 一种孟鲁司特钠片剂及其制备方法
JP2021522299A (ja) 2018-05-02 2021-08-30 フェリング・ベー・フェー 改良製剤
JP7337791B2 (ja) * 2018-06-22 2023-09-04 参天製薬株式会社 デスロラタジン又はその塩を含有する医薬組成物
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN111419820B (zh) * 2020-04-23 2022-03-25 合肥医工医药股份有限公司 一种枸地氯雷他定胶囊剂及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570306B2 (en) 1984-02-15 1988-03-10 Schering Corporation 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts.
EP0208855B1 (en) 1985-05-13 1991-03-06 Schering Corporation process for preparing piperidylidene dihydrodibenzo(a,d)cycloheptenes and aza derivatives thereof, compounds obtained by such process and the use of such compounds for preparing useful pharmaceutical compositions
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
DK0480717T3 (da) 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
BR9707369A (pt) * 1996-02-08 1999-07-20 Merck & Co Inc Formulação farmacéutica e processo para tratamento de asma de alergia e de inflamação em um paciente
TW522014B (en) 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
CN1283115A (zh) 1997-12-23 2001-02-07 先灵公司 用于治疗呼吸道和皮肤病的含有至少一种白三烯拮抗剂和至少一种抗组胺药的组合物
CN1145485C (zh) 1998-07-10 2004-04-14 先灵公司 8-氯-6,11-二氢-11-(4-亚哌啶基)-5H-苯并[5,6]环庚三烯并[1,2-b]吡啶口服组合物
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
WO2005065047A2 (en) 2003-12-23 2005-07-21 Sun Pharmaceutical Industries Limited Stable oral composition containing desloratadine
WO2006008512A2 (en) 2004-07-16 2006-01-26 Cipla Limited Anti-histaminic composition
CA2547274A1 (en) 2005-05-20 2006-11-20 Dr. Reddy's Laboratories Limited Stable desloratadine compositions
DE602006013781D1 (de) 2006-02-09 2010-06-02 Teva Pharma Stabile pharmazeutische Zubereitungen von Montelukast-Natrium
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
EP2121022A2 (en) * 2006-12-22 2009-11-25 Schering Corporation Compositions for treatment of nasal congestion

Also Published As

Publication number Publication date
WO2010021607A3 (en) 2010-06-03
EP2331079B1 (en) 2013-12-18
EP2331079A2 (en) 2011-06-15
WO2010021607A4 (en) 2010-07-22
WO2010021607A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
TR200806298A2 (tr) Farmasötik formülasyon
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1118680T1 (el) Φαρμακευτικη συνθεση
EA201401351A1 (ru) Производные бензимидазол-пролина
MX363380B (es) Formulacion de anticuerpos.
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
EA201390799A1 (ru) Триазолопиридины
MX2013003635A (es) Compuestos de n-heteroarilo.
MX342947B (es) Tratamiento de diabetes tipo 2.
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
EA201290229A1 (ru) Производные спиролактама и их применение
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
BR112012016736A2 (pt) composição , formulação farmacêutica e uso da composição"
TR201007250A2 (tr) Selobioz içeren formülasyon.
JP2009292763A5 (tr)
TR201005327A2 (tr) Sinerjik farmasötik formülasyonlar.
TR201109160A2 (tr) Eplerenon içeren yeni farmasötik kompozisyonlar.
TR200806302A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
TR200806305A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik bileşim
TR200806301A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.